Healthcare Startups funded by Y Combinator (YC) in New York 2024

Nurx is a telemedicine startup focused on increasing access to healthcare, starting with birth control and PrEP services.

Humane Genomics has developed a platform to engineer cancer killing viruses. We have taken a first principles approach to design and make oncolytic viral therapies. Using a highly lytic RNA virus engineered with "2 factor authentication" (using selective infection and selective replication) they have an on-target to off-target kill ratio > 1000. We are working on our first indication, pediatric liver cancer (hepatoblastoma), with our partners at Texas Children's Hospital, who are world leading experts. We have in vivo (mouse) data showing safety and currently developing efficacy data and are showing 50% reduction in tumor volume.

We're building curative gene therapies for kidney diseases. Our initial focus is on polycystic kidney disease (PKD), which affects 600,000 Americans and has no effective treatment or cure.

What we do? We develop digital therapeutics to address unmet medical needs in hematology and oncology. How it works? First we build networks of doctors and patients designed to track, predict and prevent disease. Second, we validate the safety and efficacy of our interventions in pivotal clinical studies to obtain regulatory clearance (SaMD). Finally, we aim to commercialize our products as prescription digital therapeutics (DTx). Where are we now? Today, we are the standard in digital hematology: * Our hemophilia network covers 33% of all patients and providers in the US. * We bested 20+ competitors, including several Fortune 500 companies. * Our clients include: Sanofi, Bayer, Novo Nordisk, Biogen, and Roche.

Wyndly (https://www.wyndly.com) fixes allergies by training patients' bodies to ignore their allergy triggers. Frustrated allergy suffers come to us when they no longer want to deal with pills and sprays. We diagnose the patient’s unique allergy profile and create a personalized treatment plan to give the patient lifelong allergy relief. Specifically, Wyndly is increasing access to sublingual immunotherapy (SLIT) for allergy care. For our patients, we're combining the convenience of telehealth and direct-to-consumer care with an exceptional patient experience that never loses the context of care. Wyndly represents an opportunity to change allergy care forever. With 60 million Americans suffering from allergies today, and with this number doubling over the coming years, there's simply an incredible need for the convenient care Wyndly provides. You can read more about us in [Techcrunch](https://techcrunch.com/2021/02/12/wyndly-aims-to-bring-allergy-drops-to-the-masses/). The Wyndly Model At Wyndly, we believe that better connections lead to better care, and we’re committed to making both happen at every step of the patient journey. Our allergy practice allows our patients to work with expert providers to develop personalized treatment plans for long-term allergy relief using clinically proven therapies. From a patient’s initial consultation to their final treatment delivery, we want the Wyndly experience to be a breath of fresh air for allergy sufferers – truly effective allergy relief, simply and efficiently delivered. Once we've conquered allergies, we're transforming the care model for every chronic condition. While transactional care for purchasing pills has flourished in telehealth, no one has gone after chronic care. Patients with chronic conditions are shuffled between providers, insurance, and more -- and they never feel heard. These patients deserve better, and we're going to give it to them. Wyndly is starting with allergies, but we'll expand into asthma, sleep apnea, and other conditions in the near future. Our values **Compassion**: We approach all our patients and partners with an open mind and a genuine desire to be of service. **Focus**: We do a few things very well, and are always clear about our boundaries and direction of travel. **Courage**: We embrace ambiguity and discomfort because we know that’s how we grow. **Progress**: We make something better every single day. *It boils down to empathy and forward momentum in everything we do.* The team Wyndly is proudly backed by Y Combinator and a leading group of angel investors and VCs. The founders are Dr. Manan Shah (Chief Medical Officer), an ear-nose-and-throat surgeon who’s a leading practitioner of telehealth in his specialty, and his cousin Aakash Shah (CEO), who led growth engineering at SparkGift (acquired by Stockpile in 2016) and Parse.ly (acquired by Automattic in 2021).

BBy's condensing device turns milk into a fine powder that spares the biome leaving it biologically and immunologically active. This allows hospitals to stop wasting precious nursing time defrosting milk for hours and milk wastage from discarding rules. Simply weigh the powder, add water, shake and serve. No more freezing, no more defrosting, only patient care. NICUs are time sensitive wards in the hospital, time is everything and yet nurses today continue to prepare frozen milk for infants in what's known as the milk shift. A shift where the nurse spends the day defrosting milk for the next shift of nurses. Our tech is now fully peer reviewed and published, yielding safe and reliable results in over 20 hospitals in the New York Tri-State. The company is headed by Vansh Langer MD, a physician (Windsor University, University of Chicago) and Blanca Aguilar Uscanga PhD, a Bioengineering/Food Science PhD (University of Guadalajara /Centro Universitario de Ciencias Exactas e Ingenierías (CUCEI)) team that has over 50 published works in the field between them and are experts in the science of infant nutrition. Vansh saw the immense need for a time critical solution in the NICU and helped solve the puzzle with Dra. Blanca and her team and decided to work together to: Nurture the Future.

H1 helps connect the healthcare ecosystem by providing a global platform of every healthcare professional and healthcare organization.

Gilgamesh is a pioneering, clinical stage mental health science-focused biotechnology company. We have a disciplined focus on developing innovative new chemical entities (NCEs) leveraging a unique combination of medicinal chemistry, intellectual property strategy, neuroscience & neurobiology, and drug development expertise. We are an experienced team, with proven success in biotech exits and inventions.

Liyfe remote symptom management platform utilizes Artificial Intelligence (AI) to automate oncology nurse triage pathways and high-risk patient detection. It helps you standardize procedures, streamline existing clinical protocols, reduced ER visits and hospitalizations.

Ophelia helps people quit opioids without going to rehab. We offer online doctor’s visits, withdrawal medication prescriptions, and support for long-term recovery, using a protocol 6x more effective than most rehabs (2/3rds of which don't have doctors). More than 3 million Americans are addicted to opioids, but 80% are not getting help, due to jobs, families, and privacy concerns. Meanwhile, there's a proven treatment that increases survival rates by 600%, and it's low cost, discreet, and convenient. It's called MAT, and it looks like treatment for anxiety or depression: medication plus therapy. However, doctors need a special waiver to prescribe the medication, which fewer than 5% of them have, so it's difficult to get, and most people are buying it on the street. Sadly, drug dealers aren't doctors: every 11 minutes another American dies of an opioid overdose, now the #1 cause of death for Americans under 50. Ophelia is replacing rehab with telemedicine, using proven science and a consumer-first approach. The opioid treatment market in the U.S. is $15B, and 85% of opioid addicts have insurance that pays for it. We're treating roughly 400 patients with thousands more waiting. Zack started Ophelia after losing his girlfriend to an opioid overdose, who found it easier to get medication from a drug dealer than a doctor. We are raising money to help patients in waiting, grow our footprint, save lives, and earn venture-level returns for investors.

**TL;DR:** Legacy (YC S19) is a startup focused on the fast-growing field of fertility and family planning. Founded at Harvard, the company has now raised $40M from leading investors like FirstMark Capital, Bain Capital Ventures, Section 32, Tribe Capital, and even celebrities like Justin Bieber, The Weeknd, and others. **What we're doing** We aim to change the outdated view that fertility is a "women's issue" by creating an accessible, affordable product for men & people with sperm. This includes everything from a mail-in kit for sperm testing & sperm freezing, personalized sperm improvement products, tele-health, DNA fragmentation analysis, supplements, and more. **Why are we the leader?** The company was founded at Harvard by a team of healthcare and fertility experts. We obsess about talent density and have out-executed our competitors over the past few years. Beyond our D2C channel, we've also unlocked: 1. Nationwide insurance coverage (10M+ lives) 2. Military contracts (Including the Navy SEALs and 15M+ veterans) 3. Employer offerings (Working with the top fertility benefit providers) **Tell me about the team** We're a team of about 30, extremely diverse (majority female, majority immigrants, strong LGBQTIA+ representation, age range of 25-65), and very values driven. Our 5 values are customer centricity, reliability, kindness, openness, and winning. Learn more about our values here: https://khaled-legacy.medium.com/legacys-values-and-why-they-matter-db116539d3da Learn more about our workplace here: https://khaled-legacy.medium.com/how-and-why-legacy-is-reinventing-workplace-benefits-9e5fda6cb863 Read about our mission to humanize the path to parenthood: https://khaled-legacy.medium.com/how-and-why-legacy-is-reinventing-workplace-benefits-9e5fda6cb863 Learn more about sperm and why it matters here: docsend.com/view/zkgk7ws

We connect healthcare workers (physicians, advanced practitioners, nurses and allied health workers) to hospitals/clinics/telehealth companies for short/full time job opportunities.

We are a drug discovery company developing a new generation of therapeutics that embrace the complexity of disease. Currently available approaches for creating drugs work on the principle of finding one drug-one protein 'magic bullets'. However, diseases such as cancer and autoimmunity are often the result of several dysregulated proteins across many distinct biological pathways. We are building a computational-experimental platform to design therapeutics that can target several disease-causing proteins at once. By designing multi-specific drugs, we are able to create therapeutics that are more efficacious and safer than existing medicines.

Isabl has developed software that can analyze the entire genome of cancer patients. Today, when people get cancer, they get a genetic test of their tumor that analyzes only a few possible mutations. With Isabl, you run the tumor through an Illumina sequencer and get the whole genome, then our software is able to analyze all the mutations. Our breakthrough technology provides unprecedented clarity into tumor biology to aid treatment planning. This opens up opportunities for precision diagnostics, disease surveillance and biomarker discovery.

Alzheimer’s is tough. And while there is no cure, getting help should be 100x easier than it is today. We’ve raised over $6 million to solve that problem. When someone is going through the disease, there are many different things they need help with (i.e. memory issues, depression, fall risk, safety in the home, etc). The primary person responsible for that care is one of the patient’s loved ones – usually a child or a spouse. That’s a really difficult thing for the loved one to do. It’s stressful, time consuming, and difficult. If we can make their lives easier, we can not only improve their experience but also create better patient outcomes. We’re building the world’s first one-stop-shop, d2c care platform for Alzheimer’s, starting by optimizing the care monitoring, management, and intervention processes.

Getting paid in healthcare is hard. Healthcare providers contract with numerous payors, all of which have their own systems and processes for authorizing payment. Worse, payor systems don't communicate with provider EMRs, so providers are forced to do a lot of manual work between them to get paid. This results in providers spending $300 Billion a year to get paid, and ultimately collect less money than what they are owed. CoreCare aggregates administrative patient data from all systems providers work with (EHR, Gov, Payer), standardizes it in our Enterprise Data Warehouse and creates a single net view of administrative patient data for the provider. Then we add workflow automations (according to client specifications) to eliminate the manual work providers are forced to do to get paid.

As healthcare costs have increased, the patient's home has become incredibly important as a site of care. Yet, patients recovering at home are highly underserved. Patients can only get better at home if they receive the high-quality care that they need reliably. The existing in-home care process involves patchwork of different vendors, all connected through faxes by nurses. We're building modern, robust software that solves this challenge and brings this market online.

C16 Biosciences is decarbonizing consumer products supply chains by producing next-generation ingredients. The company's biomanufacturing platform produces better performing, more sustainable alternatives to oils and fats, and their first product is an alternative to palm oil. The company owns and operates Palmless™ alternative fats and oils.

Nest is a lab-agnostic, comprehensive solution for organizations to launch and implement large-scale genomic programs. The platform includes the ability to triage, consent, and counsel patients for genetic testing, provide EMR-integrated clinical decision support for providers managing patients with genetic results, and manage patients’ clinical needs across the continuum of care.

Output Biosciences is pioneering Biologically-Aware Generative AI to finally understand complex biological systems. Our new generative AI architecture can handle the extremely long, nonlinear, fragmented, and high dimensional data of biological systems. We are building Large Biological Models that can generate breakthrough medicines and transform the way we diagnose, treat and prevent disease.

Serinus Biosciences is tackling one of the toughest problems in cancer treatment: creating combination therapies to override treatment resistance. We leverage cutting edge technology to design a fully explainable AI platform primed with decades of system biology knowledge. Uniquely powered for biological inference, our AI engine uncovers how cancer cells evolve treatment resistance and identifies molecules to overcome resistance escape routes. We design combinations that are safer, more effective, and can get to patients quickly. Founded by MIT PhDs and supported by a scientific advisory board of top academics from the Broad Institute, Dana-Farber, and UCSD, Serinus is powered by Y Combinator and other top investors to revolutionize precision medicine.

We provides tools, data and systems to facilitate real-time insights, decluttering outbreak detection and enhancing risk mitigation. Our surveillance is used by industry, public heath and consumers globally.

Nourish is solving America's healthcare crisis by helping people eat better. We connect chronic condition patients with a Registered Dietitian via telehealth and get it covered by their health insurance.

Ribbon Health is a health care data platform that provides the critical infrastructure that health insurers, medical providers, and digital health solutions need to enable accurate provider directories, reliable referral management, and efficient care navigation. We offer a seamless API layer that integrates into each health care organization's existing workflow to build connectivity across the industry and continuously improve the accuracy of its data with its spread and use. Ribbon is the only solution to offer all of these capabilities in one platform, and delivers the most comprehensive data on doctors, insurance plans, and the cost and quality of care culled from thousands of sources. By providing this infrastructure, Ribbon delivers on its mission of making it easy for every health care decision to be high-quality, cost effective, and convenient.

Today, biologists spend too much time pipetting by hand. We think biologists should have robots to do pipetting for them. People doing science should be free of tedious benchwork and repetitive stress injuries. They should be able to spend their time designing experiments and analyzing data. That's why we started Opentrons. We make robots for biologists. Our mission is to provide the scientific community with a common platform to easily share protocols and reproduce each other's results. Our robots automate experiments that would otherwise be done by hand, allowing our community to spend more time pursuing answers to some of the 21st century’s most important questions.

Kingdom Supercultures designs novel microbial cultures that make it easy for food manufacturers to create exciting new foods. We've developed the world's first 0-calorie fermented sodas, beers with entirely new flavors, and novel plant-based dairy replacements.

The Mednet is a physician-only Q&A platform for expert answers to real world clinical questions. With medical knowledge evolving faster than ever before, theMednet addresses the gap between textbooks and real-patient experience. At theMednet, more than 1,500 expert physicians across numerous medical specialties help answer questions that go beyond textbooks and guidelines. Our platform documents undocumented medical knowledge, while making it accessible and easily searchable to all physicians. We know patients with access to experts have better outcomes. By providing physicians with relevant, up-to-date expert knowledge, their patients benefit from the best care possible.

Measured is a telemedicine platform helping people with chronic conditions get access to affordable care. We're growing rapidly and have thousands of customers across the US.

SFA Therapeutics is creating therapeutically-tailored oral drugs that regulate the immune system from bacterial metabolites; with a focus on autoimmune diseases and cancers that originate from chronic inflammation. There are over 100 million patients who suffer from autoimmune diseases. Our treatment is designed to block the root cause of many of these chronic inflammatory diseases, with a safe oral drug.

We're a team of engineers, clinicians, and operators redesigning how healthcare fundamentally works for the 80 million uninsured and under-insured Americans. We started with a simple vertically integrated primary and urgent care health plan through a network of nurse practitioners that come directly to members virtually or through in-home visits. We designed our plan to make high-quality concierge care accessible to everyone - from the Grammy winners that have used us to our uninsured members. We're backed by world-class investors like First Round Capital, Y Combinator, Softbank along with incredible founders and operators with experience building and funding unicorns like Michael Seibel (YC, Twitch), Immad Akhund (Mercury), Allison Pickens (Gainsight), Jack Altman (Lattice), Dan Folkman (GoPuff) and others.

HistoWiz is an innovative company dedicated to accelerating pathology-based research. HistoWiz provides fast, global access to digital whole-slide images, online collaboration tools, low-cost data management, and experimental pathology expertise. The web-based platform accelerates information exchange among medical scientists and research pathologists. HistoWiz's mission is to fight cancer cooperatively instead of individually by connecting scientists and pathologists for online collaboration. The HistoWiz advantage We help your lab minimize the cost of research and maximize research productivity by providing the most efficient service for scientists to analyze experimental pathology specimens. We believe that scientists should spend their time on results interpretation rather than repetitive tissue cutting. How does it work? HistoWiz accepts formalin-fixed specimens by mail for tissue processing services. To expedite delivery of results and to facilitate global collaboration, HistoWiz offers whole-slide imaging and pathology services, allowing researchers to remotely and instantly view high-magnification images of their specimens via a secure, cloud-based “virtual microscope” on any computer or mobile device without downloading any software or gigabyte-sized files.

Eligible is the nation's first insurance billing platform built for builders. Founded in Mountain View California in 2011, Eligible's platform gives bootstrapping healthcare startups the scale of enterprise, and the Fortune 500s the agility of the hungry entrepreneur. Eligible has been listed as one of Business Insider’s 19 Hottest Startups to Watch and Katelyn has been featured in Forbes 30 Under 30 in Healthcare, Fast Company's Most Creative People in Business, and was named a Rising Star of Healthcare by Becker’s IT & CIO Review.

At Alfie, we've built a rigorous virtual medical program based on the top research from Cleveland Clinic and Harvard that allows us to precisely determine which weight loss regimen and (as needed) medications will be most effective for our members in a multimodal approach. We're optimizing exercise/nutrition/medications in complex care pathways like no one else has before. Our program has been shown to be 2x more effective than standard prescription medication and 5x more effective than habit change alone. We've raised capital from Goodwater Capital, Nina Capital, Air Force Ventures, and Phoenix Club, and various super angels including the founder of OpenTrons (medical labs automation; have raised $240 mill). Also, we're a Y Combinator graduate.

Fairway Health is an AI-assistant for health insurers to quickly process patient treatment authorizations. We use LLMs to analyze long (70+ page), messy medical records and determine if a patient is eligible for a treatment.